Status:
COMPLETED
Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Menopause
Postmenopausal Vaginal Atrophy
Eligibility:
FEMALE
45+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in North America. The purpose of this study is to determine if Vagifem Low Dose is an effective and safe treatment for patients suffering from postmenopausal atrophic vaginitis...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Postmenopausal women whose last menstruation was at least two years previously
Exclusion
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
309 Patients enrolled
Trial Details
Trial ID
NCT00108849
Start Date
March 1 2005
End Date
May 1 2007
Last Update
February 8 2017
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Mobile, Alabama, United States, 36608
2
Novo Nordisk Investigational Site
Montgomery, Alabama, United States, 36106
3
Novo Nordisk Investigational Site
Phoenix, Arizona, United States, 85050
4
Novo Nordisk Investigational Site
Tucson, Arizona, United States, 85712